<DOC>
	<DOCNO>NCT00220194</DOCNO>
	<brief_summary>Comparing effect switch Lupron Zoladex Eligard . PSA Testosterone level measure set interval determine Eligard equal well Lupron Zoladex advance Prostate Cancer patient .</brief_summary>
	<brief_title>A Six-Month , Open-Label , Crossover Study Of Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>Patient Advanced Ca , stable dose Lupron Zoladex Previous exposure Eligard .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>